Ogata K, Yokose N, Ito T, An E, Dan K, Nomura T
Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Leuk Res. 1993 Feb;17(2):137-42. doi: 10.1016/0145-2126(93)90058-s.
To evaluate the clinical usefulness of interleukin 2 (IL-2) on myelodysplastic syndromes (MDS), the serum IL-2 level, the effect of IL-2 on the proliferation of blasts, and the cell-mediated cytotoxic effect of IL-2 on blasts were examined in MDS patients. Of 18 patients, 2 patients had an increased serum IL-2 level. Although the proliferation of blasts in most cases, including the two patients having a high serum IL-2 level, was not stimulated by IL-2, the blasts of one case apparently proliferated in response to IL-2. It was also clearly shown that IL-2-stimulated normal peripheral blood mononuclear cells (PBMNC) showed cytotoxicity against MDS blasts, whereas the PBMNC of the advanced stages of MDS were usually defective in regard to this IL-2-dependent cytotoxicity. The therapeutic usefulness of IL-2 or lymphokine-activated killer cells for MDS was not established by the present study.
为评估白细胞介素2（IL-2）对骨髓增生异常综合征（MDS）的临床效用，对MDS患者检测了血清IL-2水平、IL-2对原始细胞增殖的影响以及IL-2对原始细胞的细胞介导细胞毒性作用。18例患者中，2例血清IL-2水平升高。尽管在大多数情况下，包括血清IL-2水平高的2例患者，原始细胞的增殖未受到IL-2刺激，但有1例患者的原始细胞明显对IL-2产生增殖反应。还清楚地表明，IL-2刺激的正常外周血单个核细胞（PBMNC）对MDS原始细胞显示出细胞毒性，而MDS晚期的PBMNC在这种依赖IL-2的细胞毒性方面通常存在缺陷。本研究未确立IL-2或淋巴因子激活的杀伤细胞对MDS的治疗效用。
